Cardiogen
Longevity & Cellular HealthAlso known as: Ala-Glu-Asp-Arg, AEDR, Heart Bioregulator, Cardiac Bioregulator
Mechanism
Cardiogen is a tetrapeptide bioregulator specifically designed for cardiac tissue. Part of Professor Khavinson's organ-targeted peptide series, it aims to support heart cell function by promoting repair and reducing age-related decline in cardiac tissue. Unlike drugs that address symptoms (blood pressure, cholesterol), Cardiogen works at the epigenetic level to help heart cells maintain proper gene expression as they age. It has been studied primarily in cell culture and animal models.
Technical detail
Synthetic tetrapeptide (Ala-Glu-Asp-Arg) designed as a cardiac-specific bioregulator. Unlike larger peptides that act on cell surface receptors, bioregulators penetrate to the cell nucleus where they interact with specific DNA promoter regions, modulating gene expression via chromatin remodeling (Khavinson peptide-DNA interaction hypothesis). In myocardial tissue culture: associated with changes in DNA synthesis, enhanced cardiomyocyte and fibroblast proliferation, and suppression of apoptosis via reduced p53 protein expression. Proposed to stimulate cell renewal pathways in cardiac tissue while preserving differentiated phenotype. Published preclinical data limited to in-vitro experiments and animal models from St. Petersburg Institute of Bioregulation and Gerontology.
Effects
CARDIOVASCULAR: Primary target tissue. Designed as a cardiac-specific bioregulator. In myocardial tissue culture: associated with enhanced cardiomyocyte proliferation and fibroblast activity, suggesting promotion of cardiac tissue renewal (in vitro, St. Petersburg Institute). Suppresses apoptosis in myocardial cells via reduced p53 protein expression (in vitro). Changes in DNA synthesis readouts and gene expression patterns relevant to cardiomyocyte and fibroblast pathways. Proposed mechanism: penetrates to cell nucleus where it binds specific DNA promoter regions, modulating gene expression via chromatin remodeling (Khavinson peptide-DNA interaction hypothesis). Unlike larger peptides that act on cell surface receptors, Cardiogen works at the epigenetic level. May protect against age-related cardiac remodeling (fibrosis, hypertrophy) by maintaining healthy gene expression in aging cardiomyocytes. MUSCULOSKELETAL: No direct skeletal muscle effects. Cardiac muscle specificity. NEUROLOGICAL: No direct neurological effects documented. Indirect benefits from improved cardiac output (better brain perfusion). METABOLIC: No direct metabolic effects. Improved cardiac function may support exercise tolerance and overall metabolic health. IMMUNE: No direct immune effects documented in cardiac context. ENDOCRINE: No direct endocrine effects. Tier 3: Used by anti-aging practitioners for cardiac health maintenance, particularly in patients over 50 with cardiovascular risk factors. Practitioners report it is best used preventively rather than for acute cardiac conditions. Often combined with Vesugen (vascular bioregulator) for comprehensive cardiovascular support.
Practitioner Guide
DOSING TIPS: Standard Khavinson bioregulator protocol: 10-20mg subcutaneous injection daily for 10-30 days, repeated 2-3 times per year. Also available as oral capsules — 1-2 capsules daily for 30 days. Injectable preferred by practitioners for cardiovascular applications (perceived better bioavailability for cardiac tissue targeting, though no evidence supports organ-specific delivery via SubQ). RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water. Typical concentration: 10mg/mL or 20mg/mL. INJECTION SITE: Subcutaneous — abdominal fat pad or thigh. TIMING: No specific timing. Some practitioners prefer morning to align with peak cardiac activity. SUPPLEMENT SYNERGIES: Stack with Vesugen (vascular bioregulator) for comprehensive cardiovascular support — Cardiogen for heart muscle + Vesugen for blood vessels. CoQ10 (200-400mg/day) — essential mitochondrial cofactor for cardiac energy production. Omega-3 fatty acids (EPA/DHA 2-4g/day) — anti-inflammatory and anti-arrhythmic. Magnesium glycinate/taurate (400mg/day) — supports cardiac rhythm and muscle function. Taurine (1-3g/day) — concentrated in cardiac tissue, supports contractile function. D-Ribose (5g 2-3x/day) — supports ATP regeneration in cardiac tissue. CYCLING: Course-based — 10-30 days on, 3-6 month break. 2-3 courses per year. After MI or cardiac event: some practitioners run a course during recovery (in addition to standard medical treatment, not instead of). STACKING: Cardiovascular: Cardiogen + Vesugen + CoQ10 + Omega-3. Khavinson anti-aging: Cardiogen + Epithalon + Thymalin. Post-cardiac event recovery: Cardiogen + BPC-157 (vascular healing). CONTRAINDICATION NUANCES: Do NOT use as a replacement for evidence-based cardiac medications (statins, ACE inhibitors, beta-blockers, etc.). This is complementary/adjunctive only. Patients on anticoagulants — no known interaction, but inform prescribing physician. Patients with heart failure — theoretical benefit but zero clinical data. Active myocarditis — avoid (immune modulation unknown). STORAGE: Lyophilized — room temperature or refrigerated. Capsules — room temperature. PATIENT EDUCATION: Cardiogen is a bioregulator that helps heart cells maintain healthy gene expression as they age — it does not treat heart disease directly. Think of it as preventive maintenance for cardiac tissue at the epigenetic level. It is NOT a replacement for your cardiologist or cardiac medications. Best suited for preventive use in patients over 40-50 with cardiovascular risk factors. Effects are gradual and cumulative over multiple courses. Track standard cardiac markers (troponin, BNP, CRP, lipids, EKG) to monitor overall cardiac health.
Research Summary
TIER 1 (Gold Standard): No Western RCTs exist for Cardiogen specifically. TIER 2 (Strong): Khavinson VK et al. — publications on cardiac bioregulator effects in tissue culture models (St. Petersburg Institute of Bioregulation and Gerontology). Peptide-DNA interaction studies (Khavinson et al., 2012). Published in Atlas of Science: cardiomyocyte metabolism research and Cardiogen peptide. TIER 3 (Moderate): In-vitro studies showing enhanced cardiomyocyte proliferation and reduced apoptosis. Russian clinical use data — practitioners in Russia and CIS countries have used cardiac bioregulators for 20+ years. Conference presentations at European anti-aging medicine congresses. Post-marketing surveillance from Russia. Practitioner protocols from European anti-aging clinics. KEY FINDINGS: (1) In-vitro data supports cardiac tissue renewal promotion. (2) Apoptosis suppression via p53 reduction is a plausible mechanism for cardioprotection. (3) All data is preclinical. (4) Safety profile appears excellent based on clinical use history. GAPS: No Western clinical trials. No human pharmacokinetic data. Mechanism of cardiac targeting not elucidated (how does a SubQ-injected peptide reach cardiomyocytes?). Comparison with established cardiac protectants. Long-term outcomes. ACTIVE TRIALS: None registered on ClinicalTrials.gov.